T/F: LABA are the main daily treatment for chronic COPD patients.

T/F: LABA are the main daily treatment for chronic COPD patients.

• A. True
• B. False
• C. Only during exacerbations
• D. Not recommended

Answer: (A)

In chronic COPD, daily maintenance relies on regular long-acting bronchodilation to keep airways open and reduce symptoms. Long-acting beta-agonists are a primary option for this daily maintenance, delivering sustained bronchodilation that improves dyspnea and exercise tolerance. They’re taken every day as part of ongoing management and are not for immediate relief during acute symptoms—that role belongs to short-acting rescue inhalers. Depending on how severe symptoms are and the risk of exacerbations, LABA can be used alone or in combination with other therapies such as a long-acting muscarinic antagonist or an inhaled corticosteroid. So, describing LABA as the main daily treatment reflects the standard approach of maintaining bronchodilation on a daily basis in chronic COPD.

In chronic COPD, daily maintenance relies on regular long-acting bronchodilation to keep airways open and reduce symptoms. Long-acting beta-agonists are a primary option for this daily maintenance, delivering sustained bronchodilation that improves dyspnea and exercise tolerance. They’re taken every day as part of ongoing management and are not for immediate relief during acute symptoms—that role belongs to short-acting rescue inhalers. Depending on how severe symptoms are and the risk of exacerbations, LABA can be used alone or in combination with other therapies such as a long-acting muscarinic antagonist or an inhaled corticosteroid. So, describing LABA as the main daily treatment reflects the standard approach of maintaining bronchodilation on a daily basis in chronic COPD.